1. Home
  2. QNC vs RGNX Comparison

QNC vs RGNX Comparison

Compare QNC & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QNC

Quantum eMotion Corp. Common Shares

N/A

Current Price

$2.82

Market Cap

434.7M

Sector

N/A

ML Signal

N/A

Logo REGENXBIO Inc.

RGNX

REGENXBIO Inc.

HOLD

Current Price

$10.15

Market Cap

418.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNC
RGNX
Founded
2007
2008
Country
Canada
United States
Employees
5
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
434.7M
418.1M
IPO Year
2026
2015

Fundamental Metrics

Financial Performance
Metric
QNC
RGNX
Price
$2.82
$10.15
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$28.75
AVG Volume (30 Days)
456.1K
495.7K
Earning Date
04-28-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.08
EPS
N/A
N/A
Revenue
N/A
$10,393,000.00
Revenue This Year
N/A
$51.21
Revenue Next Year
N/A
$19.08
P/E Ratio
N/A
N/A
Revenue Growth
N/A
126.48
52 Week Low
$1.90
$6.89
52 Week High
$3.41
$16.19

Technical Indicators

Market Signals
Indicator
QNC
RGNX
Relative Strength Index (RSI) 52.74 65.17
Support Level $2.57 $7.76
Resistance Level $2.96 $10.37
Average True Range (ATR) 0.18 0.54
MACD 0.01 0.10
Stochastic Oscillator 66.67 99.53

Price Performance

Historical Comparison
QNC
RGNX

About QNC Quantum eMotion Corp. Common Shares

Quantum eMotion Inc is dedicated to developing of a new generation of quantum-safe encryption for the quantum computing age. It is a developer of a new generation of cryptographic solutions under the acquisition of licenses. It allows clients and partners to develop secure quantum-safe encryption that can protect anything from consumer and enterprise devices like mobile phones, computers, the Internet of Things, and networking equipment to demanding cloud-based applications, servers, and military devices.

About RGNX REGENXBIO Inc.

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

Share on Social Networks: